Symptoms represent a return of the underlying generalized anxiety disorder rather than benzodiazepine withdrawal effects

The GAD-7 score of 12 indicates moderate anxiety severity that exceeds her baseline, suggesting the taper has unmasked the original condition that benzodiazepines were managing. The PMHNP should pause the taper, return to the previous dose of 5.25 mg daily, and add a long-term anxiolytic such as buspirone or an SSRI before reattempting any further dose reduction. Continuing the taper in the presence of moderate anxiety symptoms risks destabilizing the patient and undermining her willingness to eventually discontinue the medication. This response incorrectly attributes the symptoms exclusively to relapse of the primary anxiety disorder rather than recognizing them as expected withdrawal phenomena during benzodiazepine tapering.

Taper rate of 0.25 mg every two weeks has been too aggressive, and symptoms indicate need to slow the taper schedule

The PMHNP should convert the patient from lorazepam to an equivalent dose of a long-acting benzodiazepine such as diazepam or chlordiazepoxide to allow for smoother plasma level reductions during subsequent tapering. This conversion should be completed before any further dose reductions are attempted, and the taper schedule should be extended to monthly reductions of no more than 5-10% of the total dose. The GAD-7 score and withdrawal symptom inventory should be reassessed two weeks after the conversion to ensure stabilization before resuming the taper. While conversion to a long-acting benzodiazepine is a recognized strategy for difficult tapers, this recommendation is premature given that the patient describes her symptoms as manageable and remains motivated to continue.

Current symptoms represent predictable and tolerable withdrawal phenomena expected during a gradual benzodiazepine taper at this pace

Or perceptual disturbances indicates the taper is progressing safely. The GAD-7 score of 12 should be tracked longitudinally to differentiate transient withdrawal-related anxiety from re-emergence of the underlying disorder, with scores expected to fluctuate and gradually improve as physiological adaptation occurs. The PMHNP should continue the current taper schedule since the patient reports symptoms are manageable and motivation remains intact, while providing reassurance and psychoeducation about the expected time course of withdrawal symptoms. Implementing concurrent non-pharmacological interventions such as cognitive behavioral strategies for anxiety and sleep hygiene can support continued taper adherence.

Taper has been proceeding well and current minimal symptoms support accelerating the reduction schedule to complete discontinuation sooner

As prolonged tapers can increase cumulative withdrawal burden and extend the period of patient discomfort. Reducing the dose by 0.5 mg every two weeks instead of 0.25 mg would halve the remaining taper duration while still maintaining a gradual approach relative to abrupt discontinuation. The GAD-7 score of 12 is only mildly elevated and does not represent a clinically meaningful change that should slow the taper timeline. Faster completion of the taper would allow earlier initiation of a non-benzodiazepine maintenance medication for long-term anxiety management. Accelerating the taper rate when the patient is already experiencing moderate withdrawal symptoms is clinically inappropriate and increases the risk of severe withdrawal complications including seizures.